NI200700094A - METHODS FOR NEUROPROTECTION - Google Patents

METHODS FOR NEUROPROTECTION

Info

Publication number
NI200700094A
NI200700094A NI200700094A NI200700094A NI200700094A NI 200700094 A NI200700094 A NI 200700094A NI 200700094 A NI200700094 A NI 200700094A NI 200700094 A NI200700094 A NI 200700094A NI 200700094 A NI200700094 A NI 200700094A
Authority
NI
Nicaragua
Prior art keywords
formula
group
phenyl
alkyl
methods
Prior art date
Application number
NI200700094A
Other languages
Spanish (es)
Inventor
Roy E Twyman
Boyu Zhao
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NI200700094A publication Critical patent/NI200700094A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)

Abstract

Ésta invención está dirigida a métodos para proveer neuroprotección que comprende la administración a un sujeto en necesidad de los mismos una cantidad terapéuticamente efectiva de un compuesto seleccionado del grupo que compone la Fórmula (I) y Fórmula (II), o una sal o éster farmacéuticamente aceptable de los mismos,: Fórmula (I), Fórmula (II) en donde el fenilo es sustituido en X con de uno a cinco átomos de halógeno seleccionados del grupo que consiste en flúor, cloro, bromo y yodo; y, R1, R2, R3, R4, R5 y R6 son seleccionados independientemente del grupo que consiste en hidrógeno y alquilo C1-C4; en donde el alquilo C1-C4 es sustituido opcionalmente con fenilo ( en donde el fenilo es sustituido opcionalmente con sustituyentes seleccionados independientemente del grupo que consiste en halógeno, alquilo C1-C4, alcoxi C1-C4, amino, nitro y ciano).This invention is directed to methods for providing neuroprotection comprising administration to a subject in need thereof a therapeutically effective amount of a compound selected from the group that makes up Formula (I) and Formula (II), or a pharmaceutically acceptable salt or ester acceptable thereof: Formula (I), Formula (II) wherein the phenyl is substituted in X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and, R1, R2, R3, R4, R5 and R6 are independently selected from the group consisting of hydrogen and C1-C4 alkyl; wherein the C1-C4 alkyl is optionally substituted with phenyl (wherein the phenyl is optionally substituted with substituents independently selected from the group consisting of halogen, C1-C4 alkyl, C1-C4 alkoxy, amino, nitro and cyano).

NI200700094A 2004-10-15 2005-10-14 METHODS FOR NEUROPROTECTION NI200700094A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61940204P 2004-10-15 2004-10-15
US69840305P 2005-07-12 2005-07-12

Publications (1)

Publication Number Publication Date
NI200700094A true NI200700094A (en) 2008-02-11

Family

ID=35840528

Family Applications (1)

Application Number Title Priority Date Filing Date
NI200700094A NI200700094A (en) 2004-10-15 2005-10-14 METHODS FOR NEUROPROTECTION

Country Status (14)

Country Link
EP (1) EP1802294A1 (en)
JP (1) JP2008516961A (en)
KR (3) KR20070085309A (en)
AU (1) AU2005295787A1 (en)
BR (1) BRPI0516112A (en)
CA (1) CA2584854A1 (en)
EA (1) EA200700871A1 (en)
EC (1) ECSP077395A (en)
IL (1) IL182432A0 (en)
MX (1) MX2007004491A (en)
NI (1) NI200700094A (en)
NO (1) NO20072444L (en)
SG (1) SG142306A1 (en)
WO (1) WO2006044472A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2509596B1 (en) 2009-12-08 2019-08-28 Case Western Reserve University Gamma aminoacids for treating ocular disorders
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
KR20190081385A (en) 2017-12-29 2019-07-09 강원대학교산학협력단 Composition for preventing the ischemia stroke disease containing oxcarbazepine
KR20230044274A (en) 2020-08-31 2023-04-03 (주)바이오팜솔루션즈 Phenyl alkyl carbamate compounds for preventing or treating neurodegenerative diseases
CA3191081A1 (en) 2020-09-10 2022-03-17 Yong Moon Choi Sulfamate derivative compounds for use in treating or alleviating a psychiatric disorder

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698588A (en) * 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
US20010034365A1 (en) * 1996-01-16 2001-10-25 Choi Yong Moon Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
WO2001013904A2 (en) * 1999-08-20 2001-03-01 Ortho-Mcneil Pharmaceutical, Inc. Composition comprising a tramadol material and an anticonvulsant drug
CN1235579C (en) * 2001-02-27 2006-01-11 奥索-麦克尼尔药品公司 Carbamate compounds for use in preventing or treating neurodegenerative disorders
JP2008513466A (en) * 2004-09-16 2008-05-01 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Use of 2-phenyl-1,2-ethanediol (DI) carbamate to treat epilepsy and epilepsy

Also Published As

Publication number Publication date
CA2584854A1 (en) 2006-04-27
NO20072444L (en) 2007-06-14
BRPI0516112A (en) 2008-08-26
WO2006044472A1 (en) 2006-04-27
AU2005295787A1 (en) 2006-04-27
KR20110049901A (en) 2011-05-12
ECSP077395A (en) 2007-05-30
EP1802294A1 (en) 2007-07-04
JP2008516961A (en) 2008-05-22
SG142306A1 (en) 2008-05-28
KR20070085309A (en) 2007-08-27
EA200700871A1 (en) 2007-10-26
MX2007004491A (en) 2007-08-08
KR20090130175A (en) 2009-12-18
IL182432A0 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
NI200800008A (en) METHODS FOR NEUROPROTECTION
CO6180427A2 (en) TREATMENT OF THE GENERALIZED DISORDERS OF DEVELOPMENT
AR054524A1 (en) METHODS AND DOSAGE FORMS TO REDUCE THE SIDE EFFECTS OF CARBAMATE COMPOUNDS
ECSP088172A (en) METHODS TO TREAT EPILEPTOGENESIS
NO20071921L (en) Methods for treating epileptogenesis and epilepsy
NI200700094A (en) METHODS FOR NEUROPROTECTION
CO5601006A2 (en) PROCEDURE FOR THE PREPARATION OF ESCOPINE ESTERS
AR063015A1 (en) DERIVATIVES OF QUINAZOLINONA 5-SUBSTITUTE AND COMPOSITIONS THAT INCLUDE THEM AND METHODS TO USE THEM IN THE TREATMENT OF CANCER
NO20080877L (en) Methods for treating substance-related disorders
AR052885A1 (en) QT INTERVAL CONTROL METHODS
AR083180A1 (en) AMIDAS OF OXOPIPERAZINA-AZETIDINA AND AMIDAS OXODIAZEPINA-AZETIDINA AS INHIBITORS OF MONOACILGLICEROL LIPASA
CO6180505A2 (en) METHODS FOR THE TREATMENT OF COCLEAR AND VESTIBULAR DISORDERS
AR033426A1 (en) USE OF CARBAMATE COMPOUNDS IN THE PREVENTION OR TREATMENT OF MOVEMENT DISORDERS
IL157590A0 (en) Carbamate compounds for use in preventing or treating bipolar disorder
CO6160292A2 (en) METHODS OF TREATMENT OF DISTURBING BEHAVIOR DISORDERS 877
SE0401578D0 (en) Novel compounds
AR035757A1 (en) USE OF CARBAMATES FOR THE MANUFACTURE OF MEDICINES TO PREVENT OR TREAT A BIPOLAR DISORDER
UY29158A1 (en) METHODS OF TREATMENT OF EPILEPTOGENESIS AND EPILEPSY
PE20060559A1 (en) CARBAMATE-DERIVED COMPOUNDS FOR THE TREATMENT OF SUBSTANCE-RELATED DISORDERS
CR9766A (en) METHODS FOR THE TREATMENT OF SUBSTANCE-RELATED DISORDERS
MY136733A (en) Carbamate compounds for use in preventing or treating psychotic disorders
CY1110672T1 (en) USE OF 2- FENYL-1,2-ETHANODIOL- (DI) CARBAMIC FOR SELECTION THERAPY
AR032907A1 (en) USE OF CARBAMATE COMPOUNDS FOR THE PREVENTION OR TREATMENT OF ANXIETY DISORDERS